<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586076</url>
  </required_header>
  <id_info>
    <org_study_id>JHL-CLIN-1922-01</org_study_id>
    <nct_id>NCT03586076</nct_id>
  </id_info>
  <brief_title>A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects</brief_title>
  <official_title>A Double-Blind Randomised 2-Arm, 2-Period Crossover Study to Access the Similarity of Safety and Pharmacokinetics of JHL1922 and Pulmozyme® After Single and Repeated Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHL Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JHL Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, 2 single-doses and then repeated-dose (5 days), 2-arm,
      2-period crossover phase 1 study in 24 healthy male or female subjects. Subjects will be
      randomised to one of two treatment sequences in 2 treatment periods: JHL1922 (test treatment)
      first and then Pulmozyme (reference treatment) or Pulmozyme (reference treatment) first and
      then JHL1922 (test treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All 24 subjects will receive either JHL1922 or Pulmozyme as single doses of 2.5 mg and then
      10 mg per eRapid nebulizer, followed after a washout by a 5-period of daily dosing of 10 mg
      of either JHL1922 or Pulmozyme per eRapid nebulizer.

      The primary objective is to assess the similarity of safety and tolerability of test
      products, and the exploratory objective is to assess the similarity, if possible, of the
      systemic levels and sputum levels of dornase alfa after administration of test products.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Actual">May 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Maximum observed concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t,</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Area under the concentration-time curve (AUC) up to time t, where t is the last point with concentrations above the lower limit of quantitation (calculated for single-dose treatments only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tau</measure>
    <time_frame>up to 21 days</time_frame>
    <description>AUC over a dosing interval tau (where tau is 24 hours, calculated for the 24 hours of Day 19 only)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>JHL1922</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmozyme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JHL1922</intervention_name>
    <description>Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer</description>
    <arm_group_label>JHL1922</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dornase alfa</intervention_name>
    <description>Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer</description>
    <arm_group_label>Pulmozyme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years, inclusive

          -  Body Mass Index: 18.0-30.0 kg/m2, inclusive

          -  Weight: between 55 and 105 kg

          -  Condition: healthy; normal pulmonary function by spirometry

        Exclusion Criteria:

        - Any medical condition that presents a potential risk to the subject and/or that may
        compromise the objectives of the study, incl. active, or history of, pulmonary disorders
        incl. asthma or chronic obstructive pulmonary disease (COPD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sjoerd Van Marle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Group B.V., a PRA Health Sciences company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>6 9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>January 5, 2020</last_update_submitted>
  <last_update_submitted_qc>January 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

